Compare Liberty Global Ltd Class C (LBTYK) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liberty Global Ltd Class C vs Novo Nordisk A/S — how do they compare? Liberty Global Ltd Class C trades at $9.98 (market cap $3.48B), while Novo Nordisk A/S trades at $45.79 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 59.7× Liberty Global Ltd Class C's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Liberty Global Ltd Class C pays none. Which is the better fit depends on your goals.
| LBTYK | NVO | |
|---|---|---|
Market Cap | $3.48B | $207.85B |
Sector | Technology | Health |
52-Week High | $12.67 | $63.98 |
52-Week Low | $9.59 | $35.29 |
Enterprise Value | $10.13B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
